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Summary
Mammals mount a rapid inflammatory response to gram-negative bacteria by recognizing li-
popolysaccharide (LPS, endotoxin) . LPS binds to CD14, and the resulting LPS-CD14 complex
induces synthesis of cytokines and up-regulation of adhesion molecules in a variety of cell
types . Gram-positive bacteria provoke a very similar inflammatory response, but the molecules
that provoke innate responses to these bacteria have not been defined . Here we show that pro-
tein-free, phenol extracts ofStaphylococcus aureus contain a minor component that stimulates ad-
hesion of neutrophils and cytokine production in monocytes and in the astrocytoma cell line,
U373 . Responses to this component do not absolutely require CD14, but addition of soluble
CD 14 enhances sensitivity ofU373 cells by up to 100-fold, and blocking CD14 on monocytes
decreases sensitivity nearly 1,000-fold . Deletion of residues 57-64 of CD14, which are re-
quired for responses to LPS, also eliminates CD14-dependent responses to S . aureus molecules.
The stimulatory component of S . aureus binds CD14 and blocks binding of radioactive LPS .
Unlike LPS, the activity of S . aureus molecules was neither enhanced by LPS binding protein
nor inhibited by bactericidal/permeability increasing protein . The active factor in extracts of S .
aureus is also structurally and functionally distinct from the abundant species known as lipote-
ichoic acid (LTA) . Cell-stimulating activity fractionates differently from LTA on a reverse-
phase column, pure LTA fails to stimulate cells, and LTA antagonizes the action ofLPS in as-
says of IL-6 production . These studies suggest that mammals may use CD14 in innate responses
to both gram-negative and gram-positive bacteria, and that gram-positive bacteria may contain
an apparently unique, CD14-binding species that initiates cellular responses .
ram-positive and gram-negative bacteria provoke sim-
ilar inflammatory responses, yielding equivalent car-
diovascular abnormalities (1), similar TNF and IL-1 pro-
duction, similar tissue injury (2, 3) and death (1, 3) . In
baboons, an equivalent number of Staphylococcus aureus and
Escherichia coli are required for an LD50 (3), and in vitro,
equivalent numbers of S . aureus and E. coli are required to
initiate TNF release from monocytes (4) or macrophages
(5) . The similarity of the responses of cells to gram-positive
and gram-negative bacteria suggests a common intermediate .
The principal inflammatory component of gram-nega-
tive bacteria is LPS (endotoxin), the dominant lipid on the
outer leaflet of the outer membrane . Recent studies have
described an innate immune mechanism for responding to
LPS that involves the proteins CD 14 and LPS-binding pro-
tein (LBP)' (see reference 6 for review) . LBP (7) is a lipid
transfer protein that facilitates movement ofLPS from mi-
'Abbreviations used in this paper: AF, active fraction; BPI, bactericidal/per-
meability increasing protein ; HSA, human serum albumin; LBP, LPS-
celles to CD 14 (8) . CD14 expresses a binding site for one to
two LPS molecules, andLPS-CD14 complexes potently stim-
ulate cellular responses (8-10) . CD14 is found both as a gly-
cophosphatidylinositol-linked membrane protein on mono-
cytes andPMN (mCD14) and as a soluble form (sCD14) in
plasma, and both forms ofCD14 mediate cellular responses
to LPS (7, 8, 11, 12) .
In contrast with gram-negative bacteria, our understand-
ing of the mechanism by which gram-positive bacteria in-
duce inflammatory changes is far less developed. Most work
on inflammatory molecules of gram-positive bacteria has
centered on the cell wall and membrane because these por-
tions of the bacterium are exposed and because heat-killed
organisms and purified walls actively induce inflammation
in animal models (13) . Gram-positive bacterial walls are com-
posed of highly cross-linked peptidoglycan (PG) decorated
binding protein ; LTA, lipoteichoic acid; NHP, normal human plasma ;
PG, peptidoglycan ; rsCD14, recombinant soluble CD14 ; SACE, Staphy-
lococcus aureus crude extracts; sCD14, soluble CD14 .
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acid polymers are also linked to plasma membrane phos-
pholipids, and these lipoteichoic acids (LTA) comprise an-
other major surface component (14, 15). Gram-positive bac-
teria contain no LPS, and LTAis the majormacroamphiphile
of gram-positive bacteria. The physiochemical properties of
LTA are similar to those of LPS, and it can be extracted
with phenol by procedures similar to those used for purifi-
cation of LPS (16) .
Published work has ascribed inflammmatory activity to
each of the surface components described above. PG and
PG fragments have been shown to stimulate production of
TNF, IL-1, IL-6, and IL-8 in monocytes and macrophages
(4, 17-20) . Similarly, LTA has been shown to provoke se-
cretion of TNF, IL-1, IL-8, and NO from monocytes or
macrophages (2, 21-23) . While these data suggest a role for
the numerically dominant envelope molecules in provok-
ing inflammation, in nearly all cases very large amounts of
PG or LTA are required to stimulate responses of cells in
vitro: 1-10 Rg/ml of LTA (2, 21-23) and 10-100 la,g/ml
PG (4, 18, 20) are necessary to elicit cellular responses
while LPS elicits responses in the picogram to nanogram
per milliliter range. The low sensitivity to the purified gram-
positive products raises the possibility that a trace contami-
nant, even ifpresent as 1 part in 10,000, may be responsible
for the activity observed.
Here we show that <10 ng/ml of a trace constituent of
S. aureus strongly stimulates cytokine production in both
monocytes and the astrocytoma cell line, U373 . The re-
sponse of monocytes to extracts of S. aureus was strongly
blocked by anti-CD14. Moreover, the response of U373
cells, which do not express CD14, was strongly enhanced
by addition of sCD14. Finally, we show that the active mol-
ecule from S. aureus binds sCD14 and blocks binding of
LPS to sCD14. These data suggest the presence ofa novel,
proinflammatory, CD14-binding molecule in S. aureus.
Materials and Methods
S. aureus Crude Extracts (SACE).
￿
Phenol extracts of S. aureus
suspensions, which are commercially available as LTA from S. au-
reus, were purchased from Sigma Chemical Co. (St. Louis, MO).
They were prepared by the method of Fischer et al. (16). Briefly,
mechanically broken S. aureus were extracted with phenol at
65°C and the aqueous portion dialyzed. Nucleic acids were re-
movedby digestion with nucleases followed by reextraction, dial-
ysis, and lyophilization. This procedure, which is similar to the
Westphal procedure for purification of LPS from gram-negative
bacteria, yields not only LTA, but also some polysaccharides and
other soluble components of the cell. The material had no optical
density at either 280 or 214 nm, indicating the absence of pro-
tein. We designated this product SACE and used it as ourstarting
material. It yielded clear or slightly opalescent solutions in physio-
logic saline, and hydrolysis of 1 mg/ml of SACE (see below)
yielded 4 mM of phosphate. An abbreviated protocol was used in
one experiment (Fig. 4) . Tryptic soy broth was inoculated andin-
cubated overnight at 37°C with vigorous shaking with S. aureus
strain DSM20233 (a gift of Dr. Seva Polotsky, Yale University).
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Cultures were centrifuged, mechanically broken, and extracted
with phenol at 65°C as described above. The aqueous portion was
collected, dried down in a SpeedVac concentrator (AS160; Savant
Instruments, Inc., Farmingdale, NY), andresuspended in HZO.
Other Reagents.
￿
LPS from Salmonella minnesota strain R595
(Re) and 3H-labeled LPS from E. coli K12 strain LCD25 were
purchased from List Biologicals (Campbell, CA). Recombinant
human soluble CD14 (rsCD14) and LBP were expressed and pu-
rified as described (8). Mutant rsCD14 terminating at position
152 ofthe mature protein (rsCD141-152) and a second CD 14 mu-
tant lacking amino acids 57-64 (rsCD14o57- 64) were expressed
and purified as described (24, 25). Bactericidal/permeability in-
creasing protein 21 (BPI21) (26) was a gift of Dr. J. Weiss, New
York University. Anti-CD14 mAb 60b (27) and anti-CD18 mAb
1134 (28) were purified from ascites fluid by chromatography on
protein G-Sepharose. Fresh frozen normal human plasma (NHP)
was supplied by the New York Blood Center. Limulus amoe-
bocyte assay reagents were from BioWhittaker, Inc. (Walkers-
ville, MD), and human serum albumin was from Armour Phar-
maceutical Co. (Kankakee, IL).
Stimulation and Assay of IL-6 Production.
￿
The human astrocy-
toma cell line, U373, was obtained from the American Type
Culture Collection (HTB 17; Rockville, MD) and maintained in
RPMI 1640 medium (BioWhittaker, Inc.) supplemented with
10% FCS. U373 cells were plated in 72-well terasaki plates (Rob-
bins Scientific Corp., Sunnyvale, CA) at a density of10,000 cells/
well 24 h before stimulation. In some experiments, PBMC were
purified from the blood of healthy volunteers as described (29),
and plated in the same way2 h before stimulation. The cells were
washed extensively with AIM-V serum-free medium (GIBCO
BRL, Grand Island, NY) and then incubated with various stimuli
in AIM-V medium containing 0.5 mg/ml of human serum albu-
min (AIM-V-HSA). After 24 h, the supernatants were collected,
diluted five times in PBS containing 1 mg/ml of LISA, and IL-6
levels were quantitated usingahuman IL-6 ELISA (Biosource In-
ternational, Camarillo, CA) with slight modification. Briefly,
terasaki plates were coated with 5 ltl/well ofanti-IL-6 mAb B-E8,
40 Wg/ml, overnight at 4°C. After blocking with 0.1% gelatin, 5
RI of sample and 5 p.l of biotin-labeled anti-human IL-6 were
added per well and incubated for 2 h at 37°C. After washing,
bound antibodies were detected by adding 10 N.1/well of strepta-
vidin-conjugated alkaline phosphatase (1 :1,000; Calbiochem
Corp., La Jollu, CA), andincubating for 1 hat room temperature.
A fluorescent signal was generated using the fluorogenic substrate
Attophos (JBL Scientific, San Luis Obispo, CA) and was mea-
sured using a Cytofluor 2300 (Millipore Corp., Bedford, MA).
In some experiments, heparinized whole peripheral blood from
healthy volunteers was used for the assay. 90 LLl of the whole
blood was added to plastic tubes (Sarstedt, Inc., Newton, NC), 10
lil of various stimuli was added, and the tubes were incubated for
5 h at 37°C. After centrifugation, the supernatant was collected,
diluted five times in PBS containing 1 mg/ml of LISA, and IL-6
levels were quantitated as described above.
Assay of PMN Adhesion to Fibrinogen .
￿
Adhesion of human
PMN to fibrinogen-coated surfaces in response to LPS or SACE
fractions was measured as described (8, 30). In this assay, adhesion
of PMN in response to LPS is mediated by the leukocyte integrin
CDllb/CD18 (CR3, Macl) (30) and requires either the pres-
ence of LBP to hasten interaction of LPS with mCD14 on the
PMN or preformed LPS-sCD14 complexes made by prolonged
incubation of LPS with sCD14 (8). Briefly, mixtures containing
LPS or SACE fractions, prepared as described in the legend to Fig.
12, were diluted to 125% of their final concentrations in 40 p1
S. aureus MoleculesBind CD14 and Stimulate Cellular ResponsesHAP (Dulbecco's PBS with 0.5 U/ml aprotinin, 0.05% HSA,
3 MM a-glucose). 10 ltl offreshly isolated PMN (2 X 107 cells/
ml in HAP) fluorescently labeled with 5-(and 6-) carboxyfluores-
cein diacetate succinimidyl ester as described (30) were added and
incubated for 10 min at 37°C to stimulate the cells. PMN were
then washed into HAP and added to a72-well terasaki plate pre-
coated with fibrinogen. After 15 minat 37°C, adherenceofPMN
to the plate was quantitated: The fluorescence in each well was
determined before and after washingusing a Cytofluor2300, and
the percent adhesion was calculated from triplicate wells as (fluo-
rescence afterwashing/fluorescence before washing) X 100. Do-
nor-to-donor variation in maximal responses prohibited averag-
ing results of separate experiments, but the pattern of responses
was highly reproducible.
Phosphate Assay.
￿
The absolute amount of phosphate in sam-
ples was measured by the method of Broekman et al. (31).
Briefly, 25 la,l of sample was mixed with 100 VI perchloric acid
and digested at 180-190°Cfor 30 min. Aftercooling, 1.45 ml phos-
phate reagent (6 N H2SO4, 2.5% ammonium molybdate, 2.5%
ascorbic acid, and water mixed in a 1:1 :4 :4 ratio) was added,
samples were held at 50°C for 1 h, and 830 nm was read. The
amount of phosphate in each sample was calculated from a stan-
dard curve prepared with KH2PO4 solutions.
Column Chromatography.
￿
A C8-HPLC column (Nova-Pak C8,
3.9 nun X 150 mm, Waters Associates, Millipore Corp., Marl-
borough, MA) was equilibrated in 0.05 M sodium acetate (pH
4.7) containing 5% propanol. Sample (100 lil) was applied at a
flow rate of 0_5 ml/min, and the column was subsequently eluted
with 5-100% propanol gradient in the same buffer. 20 fractions
(1 .5 ml each) were collected, dried down in a SpeedVac concen-
trator, and resuspended in 100 ltl H2O_
Gel Electrophoresis.
￿
Tris-glycine polyacrylamide step-gradient
gels (Novex, San Diego, CA) were used for native PAGE . Sam-
plebuffers and runningbuffers were made accordingto the manu-
facturer's suggested recipes. Samples were electrophoresed at 100-
150 V for 2 h and stained with ammoniacal silver according to
published procedures (32) . 3H-LPS was visualized by fluorogra-
phy usingENHANCE (DuPont Co., Boston, MA).
Results
Extracts ofS. aureus Stimulate IL-6 Production in Monocytes.
Addition of SACE to whole blood caused a strong, dose-
dependent production of IL-6 (Fig. 1). This response was
dependent on CD14 since anti-CD14 mAb 60b strongly
blocked IL-6 production, while a control antibody, anti-
CD18 mAb 1134, was without effect. IL-6 production with
the same magnitude and CD14 requirement was observed
in parallel experiments using LPS as stimulant (not shown),
in keeping with previous work (33). This finding suggests
that crude extracts of S. aureus contain a factor that stimu-
lates monocytes in a CD14-dependent fashion.
SACE Stimulates IL-6 Secretion by U373 Astrocytoma Cell
Line in a CD14-dependent and in a CD14-independent Man-
ner. The role of CD14 in responses to SACE was further
explored in the U373 astrocytoma cell line which expresses
no mCD14. These cells secrete IL-6 in response to LPS,
but only in the presence ofexogenously addedsCD14 (12).
Monolayers of U373 cells were incubated with dilutions of
SACE for 24 h in serum-free medium in the presence or
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Figure 1.
￿
SACE induces IL-6 production in wholeblood in a CD14-
dependent manner. Whole peripheral blood was incubated for 5 h with
different concentrations ofSACE in the presence or absence of50 ltg/ml
of either control anti-CD18 mAb (IB4) or anti-CD14 mAb (60b), and
the supernatants were assayed for IL-6 by ELISA. Results are means ±
SD of triplicate determinations of a representative experiment repeated
two times.
absence of rsCD14, and the supernatant was assayed for
IL-6. High concentrations of SACE (1-10 lx,g/ml) alone
caused production of IL-6 (Fig. 2 A). The amount of IL-6
produced in response to optimal concentrations of SACE
was similar to that produced in response to LPS and sCD14
(Fig. 2 B). Addition of rsCD14 enhanced the sensitivity of
cells to SACE, with a strong response observed with as lit-
tle as 10 ng/ml SACE . The response to SACE was depen-
dent on the concentration of rsCD14 added, with strong
potentiation of both SACE and LPS responses observed
with 100 ng/ml rsCD14 (Fig. 3). The CD14-dependent
response of U373 cells to SACE was completely abolished
by the addition of blocking anti-CD14 mAbs (not shown).
These results indicate that SACE can stimulate cytokine
production in U373 cells and that CD14 can strongly po-
tentiate this response.
Cell Stimulating Activity of SACE Is Distinctfrom That of
LPS. Limulus amebocyte lysate assays showed that a stim-
ulatory dose of SACE (10 ng/ml) contained <3 pg/ml
LPS. This level is 300-fold lower than the amount of LPS
required for a comparable response. Several additional ob-
servations confirm that LPS is not responsible for cytokine
induction by SACE. (a) Phenol extracts ofculture medium
incubated overnight without a bacterial inoculum yielded
no cell-stimulating activity (Fig. 4). A parallel flask inocu-
lated with a single colony of S. aureus yielded strong, dose-
dependent, C1314-enhanced activity. The activity must,
therefore, derive from S. aureus. (b) LPS induced strong IL-6
production by U373 cells that was absolutely dependent on
the presence of rsCD14 (12, and Fig. 2 B). SACE, on the
other hand, induced IL-6 production in a CD14-indepen-
dent way (Fig. 2 A), thus distinguishing it from LPS. (c) We
observed an opposite effect of NHP on cell stimulation by
SACE and LPS. LPS activity was markedly enhanced by
adding 1% NHP (Fig. 2 D), again consistent with previousA 3000
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results (12, 34) . In contrast, NHP did not enhance the ac-
tivity of SACE (Fig. 2 Q but caused a reduction of IL-6
production at high concentrations of SACE . (d) LPS-stim-
ulated production of IL-6 by purified PBMC in serum-free
medium was strongly enhanced by LBP (7, 35, and Fig. 5
B) . Concentrations of SACE of 100 ng/ml or greater also
stimulated IL-6 production by monocytes (Fig. 5 A). How-
ever, LBP had no effect on this response, suggesting that
LBP does not recognize the active factor in SACE. This
Figure 3.
￿
CD14 enhances production of IL-6 in response to SACE.
Monolayers ofU373 cells were incubated for 24 h with either SACE (100
ng/ml, 400 nM phosphate) or LPS (100 ng/ml) in the presence or ab-
sence of different concentrations of rsCDl4. The supernatants were as-
sayed for IL-6 by ELISA. Results are means ± SD oftriplicate determina-
tions ofa representative experiment repeated three times.
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finding is consistent with the observation ofMathison et al.
(35) that LBP did not enhance the response ofmurine mac-
rophage to whole heat-killed S. aureus. (e) BPI specifically
binds LPS and blocks its ability to stimulate cells (26, and
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Figure 2. IL-6 production by
U373 cells in response to SACE
or LPS. Monolayers of U373
cells were incubated for 24 h
with different concentrations of
(A and C SACE or (B and D)
LPS in the presence (open sym-
bols) or absence filled symbols) of
either (A and B) rsCD14 (l ltg/
ml) or (C and D) 1% NHP. The
supernatant was assayed for IL-6
by ELISA. Results are means ±--
SD of triplicate determinations of
a representative experiment re-
peated three times.
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Figure 4.
￿
The cell-stimulating activity of phenol extracts derived from
S. aureus. Culture medium was incubated overnight at 37°C with vigor-
ous shaking in the presence (squares) or absence (circles) ofan inoculum of
S. aureus strain DSM20233. Both cultures were centrifuged and extracted
in an identical way with phenol as described in Materials and Methods.
The extracts were diluted to the indicated concentration ofphosphate and
were applied to monolayers ofU373 cells with or without sCD14 (1 p.g/
ml), and incubated for 24 h. Control extracts had no phosphate, but were
diluted exactly the same way for comparison. The supernatants were as-
sayed for IL-6 by ELISA. Results are means ± SD oftriplicate determina-
tions of a representative experiment repeated two times.A 2500
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Figure 5 .
￿
Effect ofSACE and LPS on IL-6 production by PBMC with or without LBP. Monolayers ofPBMC were incubated for 24 h with different
concentrations of (A) SACE or (B) LPS in the presence or absence of LBP (1 la.g/ml), and the supernatants were assayed for IL-6 by ELISA. Results are
means i' SD of triplicate determinations of a representative experiment repeated two times.
Fig. 6 B). In contrast, BPI did not significantly block CD14-
dependent stimulation of U373 cells by SACE (Fig. 6 A) .
The above experiments indicate the existence of stimula-
tory molecules in SACE that are functionally distinct from
LPS but which may nevertheless use a CD14-dependent
mechanism of cell stimulation.
SACE Components Bind rsCD14.
￿
The above studies in-
dicate that SACE contains a strong activator of IL-6 pro-
duction and that responses of both monocytes and U373
cells to this activator are enhanced by CD14. By analogy
with LPS, we hypothesized that the active component of
SACE may function by binding to rsCD14. We have pre-
viously shown that binding of LPS to rsCD14 causes a
characteristic increase in the mobility of rsCD14 on native
I7__-~
0 1'0 100 1000
SACE (ng/ml)
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gels (8) (and see Fig. 7 A). Since LPS does not cause a change
in the conformation of rsCD14 (36), we believe that the
shift in migration is caused by the strong negative charge of
LPS. Addition of SACE also caused an increase in electro-
phoretic mobility of rsCD14 (Fig. 7 A), suggesting that
SACE binds directly to sCD 14. The mobility shift ob-
served upon binding of SACE to rsCD14 was greater in
magnitude than that seen with any LPS, smooth or rough,
previously assayed (Fig. 7 A, and not shown) . This finding
suggests that SACE components bind rsCD14 and are dis-
tinct from LPS. In contrast with LPS, binding of SACE to
rsCD14 was not accelerated by the addition of LBP (not
shown), further confirming that SACE is distinct from LPS.
We also measured the ability, of SACE to compete the
B 3ooo
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Figure 6.
￿
BPI21 does not block the IL-6-inducing activity ofSACE. Monolayers ofU373 cells were incubated for 24 h with CD14 (1 Wg/ml) and dif-
ferent concentrations ofeither (A) LPS or (B) SACE in the presence or absence ofBPIZ, (200 nM). The supernatants were assayed for IL-6 by ELISA. Re-
sults are means ± SD or triplicate determinations of a representative experiment repeated two times.Figure 7 .
￿
(A) SACE causes a shift in
the electrophoretic mobility of rsCD14
in native PAGE . rsCD14 (30 jig/ml)
was incubated alone (lane 1) or with 10
or 100 Wg/ml ofLPS (lanes 2 . and 3) or
SACE (lanes 4 and 5) overnight at 37 °C
in PD-EDTA (Dulbecco's PBS lacking
divalent cations, with 1 mM EDTA) .
The samples were run on a 4-12% na-
tive polyacrylamide gel and stained with
silver . A shift in mobility of rsCD14 by
both LPS and SACE was confirmed in
parallel experiments in which the loca-
tion of rsCD14 was determined by
Western blotting (not shown) . (B)
SACE competes for binding of 3H-LPS
to sCD14. 3H-LPS (2 Wg/ml) and
sCD14 (50 Fr,g/ml) were incubated
overnight at 37 °C in PD-EDTA alone
(lane 2) or with the indicated concentrations of Re LPS (lanes 3-5), SACE (lanes 6-8), AF (lanes 9-11) or pure LTA (lanes 12-14) . 3H-LPS was incu-
bated without sCD14 to show the electrophoretic pattern offree (aggregated) LPS (lane 1) . The samples were run on an 8-16% native polyacrylamide gel
and 3H-LPS was visualized by fluorography .
binding o£3H-LPS to rsCD14 . 3H-LPS runs on native PAGE
as a high molecular weight micelle and these micelles are
well separated from rsCD14 . Complexes of 3H-LPS with
rsCD14 migrate at a low apparent molecular weight, near
the position ofrsCD14 (Fig. 7 B, lanes 1 and 2) . Addition
of unlabeled LPS blocked the binding of3H-LPS to rsCD14
as evidenced by the lack of radioactivity at the position of
3H-LPS-rsCD14 as previously reported (Fig. 7 B, lanes 3-5)
(8) . Parallel studies showed that SACE also strongly blocked
binding of 3H-LPS to rsCD14 (Fig . 7 B, lanes 6-8) . The
amount ofSACE needed to inhibit binding of 3H-LPS to
rsCD14 was lower than that for unlabeled LPS by weight,
suggesting an avid interaction of an SACE component with
the LPS-binding site ofrsCD14 .
LTA Binds sCD14 but Does Not Stimulate Cellular Re-
sponses . The dominant component in SACE is LTA, a hpid-
linked glycerol-phosphate polymer with a well-defined
structure (15) . Reverse-phase HPLC of SACE yielded a
dominant peak (70% ofphosphate applied to column) at a
position expected for LTA (Fig. 8, fractions 11 and 12) .
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We confirmed that this peak is LTA by measuring equimo-
lar glycerol and phosphate in base hydrolyzates of the frac-
tions (Kusunoki, T ., and S.D . Wright, unpublished obser-
vations) . Purified LTA competitively displaced 3H-LPS
from sCD14 (Fig . 7 B) and caused a shift in mobility of
sCD14 (not shown), indicating that it binds to sCD14 . The
purified LTA, however, did not stimualte U373 cells either
in the absence (Figs . 8 and 9) or the presence (Fig. 9) of
sCD14 . Similarly, purified LTA failed to stimulate IL-6
production in monocytes (not shown) or adhesion inPMN
(see below) . The inability of LTA to stimulate cytokine
production is consistent with the data of Keller et al . (23)
who showed that highly purified LTA from S . aureus was
incapable ofstimulating NO secretion from macrophages .
The biosynthetic precursor of LPS known as lipid IVa
also binds to sCD14 (8) but does not stimulate cytokine
synthesis in human cells . Rather, it acts as an LPS antago-
nist, inhbiting responses of cells to complete LPS (37) . In a
similar fashion, we observed that LTA caused a dose-depen-
dent inhibition ofLPS-stimulated, CD14-dependent IL-6 re-
S . aureus Molecules Bind CD14 and Stimulate Cellular Responses
Figure 8 .
￿
Purification of the stimulatory components of
SACE with C8-HPLC . SACE (14 mM phosphate X 100 WI)
was applied to a reverse-phase HPLC C8 column and eluted
with a 5-100% propanol gradient. 20 fractions were col-
lected and assayed as described in Materials and Methods.
For the IL-6 assay, each fraction was further diluted 100-fold
with AIM-V-HSA medium and applied to U373 monolay-
ers . Results are means oftriplicate determinations ofa repre-
sentative experiment repeated three times .7000
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Figure 9.
￿
CD14-dependent and -independent activities of fractions 1
and 12 from C8 HPLC. Fractions 1 and 12 from C8 HPLC were diluted
to the indicated concentrations of phosphate in AIM-V-HSA medium
and applied to U373 monolayers with or without rsCD14 (1 lr,g/nil). Af-
ter a 24-h incubation, IL-6 in the supernatant was assayed by ELISA. Re-
sults are means ± SD of triplicate determinations of a representative ex-
periment repeated three times.
lease from U373 cells (Fig. 10) . This observation confirms
that LTA does not stimulate cells and suggests that, by
binding CD14, LTA may blunt responses to LPS. More
importantly, it indicates that the active factor in SACE
must be distinct from LTA.
Purification of the Active Factor in SACE.
￿
The chromato-
gram of SACE showed that all cell-stimulating capacity ap-
peared in a single peak (Fig. 8, fraction 1) that was well
separated from LTA. This peak contained 20% of the total
applied phosphate and caused both CD14-dependent and
CD 14-independent stimulation of U373 cells in a dose-
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Figure 10. Pure LTA antagonizes the activity LPS. LPS (1 ltg/ml),
sCD14 (10 Wg/ml), LBP (1 jig/ml), and different concentrations ofpure
LTA were rnixed and incubated at 37°C overnight. The mixtures were
then diluted 100-fold and applied to U373 monolayers and further incu-
bated for 24 h. The x-axis depicts the final concentration of pure LTA
present with cells. The supernatants were assayed for IL-6 by ELISA. Re-
sults are means ± SD of triplicate determinations of a representative ex-
periment repeated two times. The inhibitory effect of LTA is likely to be
due to competition with LPS binding for sCD14 since the potency of
LTA as an inhibitor was reduced -100-fold if the preincubation step
with sCD14 was omitted (data not shown).
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dependent fashion (Fig. 9). Fraction 1 also bound sCD14 as
shown by its ability to shift the mobility ofsCD14 in native
PAGE (not shown) and by its ability to block binding of
3H-LPS to sCD14 (Fig. 7, lanes 9-11). These results sug-
gest that fraction 1 contains the biologically active species
in SACE. Since this active fraction (AF) is distinct from
LTA, we suggest that it may contain a novel gram-positive
compound.
Approximately 20% of the original IL-6-inducing activ-
ity was recovered in fraction 1 asjudged by dose-dependence
data (not shown) . We noted, however, that LTA effectively
antagonized the action ofAF (not shown), and thus any ad-
ditional activity that may have eluted with LTA would not
have been detected because ofthis antagonist activity.
AF Interacts u4th a Site in the Amino Terminus of CD14.
Previous work has suggested that only the amino-terminal
152 residues of sCD14 are necessary for biological activity
since residues 153-346 of rsCD14 (the carboxy-terminal
two-thirds of the molecule) can be deleted without affect-
ing its ability to mediate cellular responses to LPS (24). In a
parallel fashion, we found that rsCD 1 41-152 enabled re-
sponses of U373 cells to AF with concentration depen-
dence similar to that of full-length rsCD14 (Fig. 11). These
studies indicate that residues in the carboxy-terminal two-
thirds ofrsCD14 are not necessary for the interaction ofAF
with rsCD14. Additional recent studies have identified res-
idues 57-64 as crucial to the function ofsCD14 (25) . Dele-
tion of these residues leads to a mutant (CD14o57- 64) that
cannot mediate cellular responses to LPS, and in a parallel
fashion, we found that rsCD14o57- 64 did not enable re-
sponses of U373 cells to AF (Fig. 11). This finding indicates
that AF requires residues 57-64 of CD 14 to stimulate cells.
AF-isCD 14 Complexes Stimulate Neutrophils.
￿
LPS causes
a rapid, CD14-dependent enhancement of integrin-medi-
ated PMN adhesion (8, 11). Because adhesion is measured
after exposure of PMN to LPS for only 10-20 min, LPS
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Figure 11 .
￿
rsCD14,_152, but not rsCD14o5214, induces a dose-depen-
dent cell-stimulatory activity ofAF. Monolayers ofU373 cells were incu-
bated for 24 h with AF (400 nM phosphate) in the presence or absence of
different concentrations of either rsCD14, rsCD14,-152, or rsCD14o52- 64-
The supernatant was assayed for IL-6 by ELISA. Results are means ± SD
of triplicate determinations of a representative experiment repeated two
times.alone is ineffective and a response is only observed ifLBP is
added to speed movement of LPS into CD14 or if pre-
formed LPS-sCD14 complexes are used (8) . In a parallel
fashion, we observed that AF alone did not stimulate
PMN, but incubation ofAF with sCD14 overnight to form
AF-sCD14 complexes lead to strong stimulation (Fig. 12).
To our knowledge, this is the first demonstration that gram-
positive molecules may directly stimulate leukocyte inte-
grin function in PMN. To determine if formation of AF-
rsCD14 complexes was required for stimulation of PMN,
AF and rsCD14 were mixed and added immediately to
PMN, without time for binding of AF to rsCD14. Under
these conditions, AF caused no PMN adhesion (Fig. 12) .
This observation suggests that binding of AF to sCD14 is a
prerequisite for efficient PMN stimulation. We have ob-
served in addition that pure LTA alone (not shown) or pre-
incubated with rsCD14 (Fig. 12) failed to stimulate PMN
adhesion, confirming that AF, not LTA, comprises the bio-
logically active species in SACE.
Discussion
A large number of reports have described cytokine syn-
thesis in response to bacterial cells or extracts (1-5, 13, 17-23,
and see reference 38 for review), and several recent reports
have implicated CD14 in these responses. Lipoarabinoman-
nan from Mycobacterium tuberculosis stimulates TNF and IL-1
production from monocytes, and this response is blocked
by anti-CD14 mAbs (39) . Similarly, manuronic acid poly-
mers from Pseudomonas (40), soluble peptidoglycan frag-
ments from S. aureus (41), rhamnose-glucose polymers from
Streptococcus mutans (42), chitosans from arthropods (43),
and insoluble cell walls from several gram-positive species
(44) have been shown to induce a cytokine response in
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1/5000 1/500 1/50
Dilution
Figure 12.
￿
AF-rsCD14 complexes stimulate adhesion of PMN to fi-
brinogen. sCD14 (500 Wg/ml) was incubated overnight at 37°C in PBS
with AF (1 .5 mM phosphate)(-E-), pure LTA (1 .5 mM phosphate)
or LPS (5 pg/ml)
￿
As control, AF was preincubated
without rsCD14 (-0-). The samples were diluted 50-, 500-, or 5,000-
fold, added to PMN, and adhesion of PMN to fibrinogen was measured
as described in Materials and Methods. To determine ifovernight incuba-
tion ofAF wtih rsCD14 was necessary to observe cell stimulation, AF was
mixed with sCD14 and added immediately to the PMN for assay (-4&-).
monocytes, and all these responses can be blocked with anti-
CD14 antibodies. The studies reported here confirm a role
for CD14 in responses of monocytes, PMN, and U373
cells to S. aureus. Addition ofsCD14 enhanced responses of
U373 cells by up to 100-fold, and blockade of CD14 de-
creased sensitivity of monocytes by ^-1,000-fold. These
studies suggest that the role ofCD14 is to enhance the sen-
sitivity ofresponses that can occur in the absence of CD14.
Additional experiments have suggested that stimulatory
microbial substances may bind to CD14. Manuronic acid
polymers compete with anti-CD14 for binding to mono-
cytes (40), and sCD14 binds to insoluble walls of Streptococ-
cus mitis (44) . Our studies offer unequivocal evidence that
molecules from S. aureus bind sCD 14. They further show
that binding to CD14 is necessary for enhancement of sen-
sitivity to these molecules, and that residues 57-64 of CD14,
previously defined as a binding site for LPS, are necessary
for CD14 to enhance responses to S. aureus molecules.
Our studies extend previous work in that we have spe-
cifically sought the bacterial molecule that binds CD14 and
stimulates cells . While prior authors have been meticulous
in excluding LPS from their preparations, the whole bacte-
ria, cell walls, or cell wall fragments used in past studies are
inherently heterogeneous, and it is not possible to exclude
a highly active subspecies as the source of the biological ac-
tivity. We have observed that a minor component in ex-
tracts of S. aureus bears all of the cell-stimulating activity in
the extract. This component has no optical density or other
characteristic by which its presence could be detected. There-
fore, it is possible that such a molecule may have been the
source of the stimulatory activities reported for other bacte-
rial preparations. In keeping with this hypothesis, Tsutsui et
al. (45) and Kotani et al. (46) recently fractionated LTA from
Enterococcus hirae and found cytokine-inducing activity only
in the most lipophilic fractions. However, synthetic LTA
molecules with the structure predicted from their studies
did not have biological activity (47). It is thus clear that a
minor, uncharacterized component ofgram-positive bacte-
ria may express the inflammatory activity. The precise struc-
ture of the active molecule is thus of considerable interest
and is currently under study.
CD14 appears to serve in enhancing responses to an un-
expectedly broad range of pathogens, and Pugin et al. (44)
have suggested that CD14 may act as a "pattern recogni-
tion" receptor capable of binding and mediating responses
to a broad range ofbacterial molecules. Our results confirm
a role for CD14 in binding and mediating responses to mol-
ecules other than LPS, but it is not clear that CD14 pro-
vides the specificity needed to discriminate LPS or AF from
similar host molecules such as gangliosides or phospholip-
ids. Indeed, CD14 binds inactive LPS analogues (8, 48), in-
active LTA species (Fig. 5 B), and certain phospholipids
(Hailman, E., and S. D. Wright, unpublished observations) .
Moreover, CD14 has been shown not to discriminate be-
tween LPS variants with opposite biological effects (49),
and additional cellular molecules must contribute recogni-
tion specificity (48, 49). How could CD14 enhance re-
sponses to bacterial molecules without the recognition spec-
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that, by sequentially binding and releasing LPS, sCD14
serves to shuttle LPS from micelles into HDL particles (9)
or lipid membranes (Wurfel, M.M., and S.D . Wright, manu-
script in preparation) . This type of shuttle action may thus
concentrate LPS or AF in the membrane of a sensitive cell
and facilitate recognition by additional cellular molecules.
By concentrating a subset of bacterial molecules at the cell
surface, CD14 may contribute both to the sensitivity and
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